Pharmacokinetics of muzolimine after acute and chronic dosing in hypertensive patients with mild renal insufficiency.
Pharmacokinetics and clinical effects of muzolimine were investigated in 6 hypertensive patients with incipient renal insufficiency. Muzolimine plasma levels were determined after the first dose and after 8 weeks of treatment with muzolimine (20 mg o.d.). The area under the curve of muzolimine plasma levels was greater after 8 weeks than after the first dose. Also, peak plasma concentrations were higher after 8 weeks; however, muzolimine half-lives in the beta-phase were unchanged. Blood pressure and body weight decreased with time. Muzolimine was well tolerated.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007674:Kidney Diseases / Q000150:complications*; D007700:Kinetics; D008875:Middle Aged; D009156:Muzolimine / Q000097:blood* / Q000627:therapeutic use; D011720:Pyrazoles / Q000097:blood*; D013997:Time Factors
D011720:Pyrazoles; D009156:Muzolimine; D003404:Creatinine